Seer, Inc. (NASDAQ:SEER – Get Free Report) CFO David Horn sold 6,797 shares of the stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $1.97, for a total transaction of $13,390.09. Following the completion of the sale, the chief financial officer directly owned 436,802 shares in the company, valued at approximately $860,499.94. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Seer Trading Up 1.5%
SEER stock opened at $1.97 on Friday. The stock has a market cap of $109.91 million, a PE ratio of -1.45 and a beta of 1.59. Seer, Inc. has a 12 month low of $1.62 and a 12 month high of $2.63. The company has a 50-day moving average price of $2.17 and a 200 day moving average price of $2.12.
Seer (NASDAQ:SEER – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. Seer had a negative net margin of 484.51% and a negative return on equity of 25.88%. The business had revenue of $4.12 million during the quarter, compared to the consensus estimate of $4.00 million. Seer has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Seer, Inc. will post -1.42 EPS for the current year.
Hedge Funds Weigh In On Seer
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on SEER
About Seer
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
See Also
- Five stocks we like better than Seer
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MP Materials Stock Soared After Earnings—Here’s the Real Reason
- Quiet Period Expirations Explained
- Why Palantir Slide May Be a Setup for a Long-Term Opportunity
- How to Profit From Growth Investing
- Attention Income Investors: This REIT Is on Sale
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
